Goodyear Tire & Rubber Co vs Novavax Inc — how do they compare? Goodyear Tire & Rubber Co trades at $4.68 (market cap $1.37B), while Novavax Inc trades at $12.5 (market cap $1.82B). The key difference: Novavax Inc is the larger of the two by market cap, and Novavax Inc is trading nearer its 52-week high, Goodyear Tire & Rubber Co nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Goodyear Tire & Rubber Co for 57 Days and Novavax Inc for 59 Days on average.
| GT | NVAX | |
|---|---|---|
Market Cap | $1.37B | $1.82B |
Volume | 9,470,773 | 6,198,505 |
Sector | Consumer Cyclical | Health |
52-Week High | $10.54 | $12.56 |
52-Week Low | $4.66 | $6.22 |
Typical Hold Time | 57 Days | 59 Days |
Enterprise Value | $8.72B | $1.39B |
Signals from Pluang's Aura AI — not financial advice
Goodyear (GT) trades at $4.68, down 0.21% on the day, with a bearish technical signal and weak profitability metrics including a negative net income margin and ROE. Recent earnings show mixed results, with a Q2 2026 loss of $0.61 per share beating expectations but revenue declining. The company's restructuring efforts focus on premium tire segments and cost management, while cash flow trends show modest improvement with a net cash flow of $46 million in 2025.
The outlook remains challenging due to persistent losses and high debt, but analyst consensus suggests upside with a $8.00 price target. Key risks include volume pressure, competitive threats, and execution of the turnaround plan. Investment opportunity hinges on successful margin expansion and debt reduction, though near-term volatility is likely amid macroeconomic headwinds.
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →